Yazar "Sen, Erdem" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    HER-2 Mutations in Non-Small Cell Lung Cancer
    (YERKURE TANITIM & YAYINCILIK HIZMETLERI A S, 2018) Sen, Erdem; Yavas, Guler; Ata, Ozlem
    Lung cancer is a heterogeneous and complex disease. Oncogenic driver mutations are critical for lung cancer development and serve as therapeutic targets. Oncogenic driver mutations are well defined in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and reactive oxygen species-1 (ROS-1) mutations. Human epidermal growth factor receptor-2 (HER-2) positivity and anti-HER-2 treatments are well studied in breast cancer. In non-small cell lung cancer (NSCLC), these treatment approaches are under investigation. In NSCLC, mutations of HER-2 are found in 2%-4% of cases. The most commonly encountered mutations are frame insertions in exon 20. There is no evident association between HER-2 amplification and HER-2 mutations. HER-2-targeted therapy needs further clinical investigations in NSCLC.
  • Küçük Resim Yok
    Öğe
    Incidentally Detected Kaposi Sarcoma of Adrenal Gland with Anaplastic Features in an HIV Negative Patient
    (HINDAWI LTD, 2016) Celik, Zeliha Esin; Celik, Murat; Sen, Erdem; Cebeci, Hakan; Ata, Ozlem; Yavas, Cagdas
    Kaposi sarcoma (KS), a vascular tumor caused by infection with human herpesvirus 8 (HHV8), is a systemic disease that can present with cutaneous lesions with or without visceral involvement. Very few cases of KS, most of which were associated with AIDS, have been reported in the adrenal gland. Anaplastic transformation of KS is a rare clinical presentation known as an aggressive disease with local recurrence andmetastatic potential. We report here a 47-year-oldHIV negativemale presented with extra-adrenal symptoms and had an incidentally detected anaplastic adrenalKS exhibited aggressive clinical course. To the best of our knowledge, this is the first case of anaplastic primary adrenal KS withoutmucocutaneous involvement but subsequently developed other side adrenal metastases in an HIV negative patient.
  • Küçük Resim Yok
    Öğe
    Neutropenic Fever, Skin and Eye Toxicities Develops During Docetaxel Treatment in Metastatic Prostate Cancer: A Case Report
    (GALENOS YAYINCILIK, 2017) Sen, Erdem; Oner, Irem; Ata, Ozlem
    Prostate cancer is one of the most common tumors in men. Docetaxel and prednisone treatment are accepted as standard therapy in castration-resistant prostate cancer patients. Docetaxel is a chemotherapeutic drug of the taxane group that inhibits depolymerization of tubulin and has an antitumoral activity through stabilization of microtubules. It has also been reported that docetaxel therapy lead to cutaneous and eye side effects besides systemic side effects. Skin and eye toxicities are more common with weekly docetaxel treatment than three-week regimens. We would like to present our case of neutropenia, eye and skin toxicities with docetaxel chemotherapy treatment which is commonly used in metastatic prostate cancer patients.